Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma
Author:
Funder
Berlin Mathematical School
Merck
Sanofi-Aventis Deutschland
Roche
Servier
Bayer
GlaxoSmithKline
Merck KGaA
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference78 articles.
1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018;Ferlay;Eur J Cancer,2018
2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010
3. Novel HER2-directed treatments in advanced gastric carcinoma: AnotHER paradigm shift?;Ricci;Cancers,2021
4. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study;Shitara;Lancet Oncol,2019
5. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (Pts) with advanced/metastatic HER2+ gastric cancer (GC)/Gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03;Janjigian;J Clin Orthod,2022
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma;JAMA Network Open;2024-01-23
2. Development and Preclinical Evaluation of [68Ga]BMSH as a New Potent Positron Emission Tomography Tracer for Imaging Programmed Death-Ligand 1 Expression;Pharmaceuticals;2023-10-19
3. Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects;International Journal of Molecular Sciences;2023-10-18
4. Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery;Frontiers in Genetics;2023-08-11
5. Immunotherapy for gastroesophageal cancer;Oncology in Clinical Practice;2023-06-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3